Disease
|
Tests
|
Evidence linking to NTMLD
|
Bronchiectasis, COPD, silicosis, pneumoconiosis, previous TB
| HRCT | Cohort studies 24, 30, prevalence studies 22, 23, 26–28, case series 25, 29 |
Cystic fibrosis
| Sweat chloride, CFTR genotyping | Cohort studies 33, case–control studies 34–39, prevalence studies 40–45 |
GORD
| 24-h pH monitoring (and other diagnostic tests) | Two prevalence studies 46, 47 |
Deficiencies in IFN-γR1, IFN-γR2, IL-12, IL-12R
| Tests of IFN-γ production in response to mycobacterial antigens, other specialised immunological tests, genotyping | Case reports and series 48–52; no evidence for isolated lung disease |
STAT1 deficiency
| Tests of cellular response to exogenous IFN | Case reports 53, 54; no evidence for isolated lung disease |
Chronic granulomatous disease
| Tests of neutrophil function (e.g. nitroblue tetrazolium) | One case report 55 |
HLA types associated with NTM disease
| HLA genotyping | One prevalence study 56, one cohort study 57 |
SLC11A1 polymorphisms
| SLC11A1 genotyping | One case series 58 |
CFTR heterozygosity
| CFTR genotyping | Prevalence studies 59, 60, one case–control study 61 |
α1-AT deficiency
| Serum α1-AT | No direct evidence |
VDR polymorphisms
| VDR genotyping | One case series 62 |
Vitamin D deficiency
| Serum vitamin D | No direct evidence |
Coeliac disease
| Coeliac autoantibodies and serum IgA | No direct evidence |
HIV infection
| HIV serology | Cohort studies 63, prevalence studies 64, case series 23, 65–68 |
Inhibitory anti-IFN-γ antibodies
| Anti-IFN-γ antibodies | One case series 69 |